Filing Details
- Accession Number:
- 0001562180-24-004025
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-05-14 16:04:58
- Reporting Period:
- 2024-05-13
- Accepted Time:
- 2024-05-14 16:04:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1517022 | Akebia Therapeutics Inc. | AKBA | Pharmaceutical Preparations (2834) | 208756903 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1669737 | Michel Dahan | C/O Akebia Therapeutics, Inc. 245 First Street Cambridge MA 02142 | Svp, Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2024-05-13 | 34,840 | $1.26 | 672,092 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.
- This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2023.
Billionaire Hedge Funds
